Skip to content

Valneva

  • Über uns
    Über uns Advancing vaccines for better lives Mehr lesen
    • Unsere Strategie
    • Unsere Verantwortung
    • Unser Team
  • Produkte
    Produkte Focusing on vaccines for infectious diseases with major unmet needs Mehr lesen
    • Japanische Enzephalitis-Impfstoff
    • Cholera-Impfstoff
    • COVID-19 Impfstoff
    • Marketing und Vertrieb
    • Produktion und Dienstleistungen
  • F&D
    F&D Dedicated to innovation in vaccine research and development Mehr lesen
    • Pipeline
    • Lyme Borreliose – VLA15
    • Chikungunya – VLA1553
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
    • Expanded Access-Richtlinie
    • Wissenschaftliche Publikationen
  • Investoren
    Investoren Mehr lesen
    • Events und Präsentationen
      • Kalender
      • Präsentationen des Unternehmens
    • Financial & Filings
      • Finanzberichte
      • SEC Filings
    • Pressemeldungen
    • Corporate Governance
      • Corporate Governance
      • Corporate Compliance & Ethics
    • Vorgeschriebene Informationen
    • Aktieninformation
      • Aktienkurs
      • Analysten
      • Aktionärsstruktur
      • Delisting von der Wiener Börse
    • Hauptversammlungen
      • 2022 Kombinierte Hauptversammlung
      • June 23, 2022 Special Meeting
      • Archiv Hauptversammlungen
    • Videos und Webcasts
    • Häufig gestellte Fragen
    • Kontakt
  • Medien
    Medien Pressemeldungen, Aktuelles und Ressourcen für Medien Mehr lesen
    • Pressemeldungen
    • In den Nachrichten
    • Ressourcen für Medien
    • Medienkontakte
  • Karriere
Kontakt
  • EN
  • FR
  • | DE
Search

Month: January 2022

Posted on January 20, 2022January 26, 2022
Posted on January 11, 2022January 26, 2022
Posted on 6. Jänner 2022January 10, 2022

Translation


by Transposh - Übersetzungs-Plug-In für WordPress

Recent Posts

  • Chikungunya and Lyme vaccines make headway
  • Chikungunya Vaccine Candidate Completes BLA Submission to U.S. FDA
  • Lyme disease vaccine edging closer with Valneva and Pfizer data
  • Valneva eyes first place in chikungunya vaccine race
  • After Covid setback, Valneva lines up $100M for Pfizer-allied Lyme disease PhIII

Recent Comments

    Archives

    • January 2023
    • December 2022
    • October 2022
    • September 2022
    • August 2022
    • July 2022
    • June 2022
    • May 2022
    • April 2022
    • March 2022
    • February 2022
    • January 2022
    • November 2021
    • October 2021
    • September 2021
    • August 2021
    • July 2021
    • June 2021
    • May 2021
    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • December 2020
    • October 2020
    • September 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • January 2020
    • September 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • February 2019
    • January 2019
    • December 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018

    Categories

    • C. difficile
    • Chikungunya
    • COVID-19
    • DUKORAL®
    • IXIARO®
    • Lyme Borreliose
    • Unkategorisiert

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Valneva

    • Über uns
    • Produkte
    • F&D
    • Investoren
    • Medien
    • Karriere
    Weitere Websites
    • Valneva Canada
    • Valneva UK
    • Valneva Austria
    • Valneva USA
    • Valneva Nordic
    • Valneva France
    Kontakt
    © 2023 Valneva SE. All rights reserved.
    • Legal Notice
    • Cookie Policy
    • Privacy Policy
    • Terms of Use
    • 1907-00-VLA-002 | 11-JUL-2019
    We use cookies to improve the functionality and user experience of the website and to analyse the traffic. You can find detailed information in our Privacy Policy.
    ACCEPT CHANGE MY PREFERENCES
    Privacy & Cookies Policy

    Your privacy is important to us

    Cookies are very small text files that are stored on your computer when you visit a website. We use cookies for a variety of purposes and to enhance your online experience on our website (for example, to remember your account login details).

    You can change your preferences and decline certain types of cookies to be stored on your computer while browsing our website. You can also remove any cookies already stored on your computer, but keep in mind that deleting cookies may prevent you from using parts of our website.

    More information

    For any queries in relation to our policy on cookies and your choices, please contact us.

    To find out more, please visit our Cookies Policy.
    Strictly necessary cookies
    Always Enabled
    These cookies are essential to provide you with services available through our website and to enable you to use certain features of our website.

    Without these cookies, we cannot provide you certain services on our website.
    Tracking and performance cookies
    These cookies are used to collect information to analyze the traffic to our website and how visitors are using our website.

    For example, these cookies may track things such as how long you spend on the website or the pages you visit which helps us to understand how we can improve our website site for you.

    The information collected through these tracking and performance cookies do not identify any individual visitor.
    SAVE & ACCEPT